MDT

97.38

+1.94%↑

VEEV

296.3

-0.48%↓

142.16

+2.17%↑

HQY

88.77

-1.93%↓

PHR.US

23.46

+4.13%↑

MDT

97.38

+1.94%↑

VEEV

296.3

-0.48%↓

142.16

+2.17%↑

HQY

88.77

-1.93%↓

PHR.US

23.46

+4.13%↑

MDT

97.38

+1.94%↑

VEEV

296.3

-0.48%↓

142.16

+2.17%↑

HQY

88.77

-1.93%↓

PHR.US

23.46

+4.13%↑

MDT

97.38

+1.94%↑

VEEV

296.3

-0.48%↓

142.16

+2.17%↑

HQY

88.77

-1.93%↓

PHR.US

23.46

+4.13%↑

MDT

97.38

+1.94%↑

VEEV

296.3

-0.48%↓

142.16

+2.17%↑

HQY

88.77

-1.93%↓

PHR.US

23.46

+4.13%↑

Kodu・Aktsiate loetelu・Fulgent Genetics Inc

Fulgent Genetics Inc

Avatud

SektorTervishoid

22.68 -1.13

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

22.57

Max

23.24

Põhinäitajad
By Trading Economics
Sissetulek	-7.4M -19M
Müük	8.3M 82M
Kasumimarginaal	-23.539
Töötajad	1,313
EBITDA	-3.5M -15M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+7.79% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. nov 2025

Turustatistika
By TradingEconomics
Turukapital	143M 691M
Eelmine avamishind	23.81
Eelmine sulgemishind	22.68

Uudiste sentiment

By Acuity

50%

149 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

17.32 / 19.04 Toetus ja vastupanu

Fulgent Genetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. okt 2025, 23:30 UTC

Kuumad aktsiad

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. okt 2025, 21:21 UTC

Tulu

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. okt 2025, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. okt 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. okt 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. okt 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. okt 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Scales's JV Buyout Lauded by Bull -- Market Talk

2. okt 2025, 22:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Forex and Fixed Income Roundup: Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. okt 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. okt 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. okt 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

2. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. okt 2025, 20:49 UTC

Omandamised, ülevõtmised, äriostud

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. okt 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. okt 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. okt 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. okt 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. okt 2025, 18:46 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. okt 2025, 18:45 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. okt 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. okt 2025, 18:43 UTC

Omandamised, ülevõtmised, äriostud

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Võrdlus sarnastega

Hinnamuutus

Fulgent Genetics Inc Prognoos

Hinnasiht

By TipRanks

7.79% tõus

12 kuu keskmine prognoos

Keskmine 25.33 USD 7.79%

Kõrge 30 USD

Madal 21 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fulgent Genetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Fulgent Genetics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

17.32 / 19.04Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

The bullish and bearish events are balanced.

Sentiment

By Acuity

149 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.